HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Dichlorodiphenyldichloroethane (DDD)

An organochlorine insecticide that is slightly irritating to the skin. (From Merck Index, 11th ed, p482)
Also Known As:
DDD; TDE; Benzene, 1,1'-(2,2-dichloroethylidene)bis(4-chloro-)
Networked: 1245 relevant articles (67 outcomes, 148 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Smith, Richard J H: 11 articles (11/2014 - 09/2007)
2. Zhang, Yuzhou: 7 articles (11/2014 - 11/2010)
3. Sethi, Sanjeev: 7 articles (06/2014 - 09/2007)
4. Padeletti, Luigi: 6 articles (06/2015 - 03/2004)
5. Pickering, Matthew C: 6 articles (06/2014 - 09/2007)
6. Chan, Danny: 5 articles (09/2015 - 12/2005)
7. Cheung, Kenneth M C: 5 articles (09/2015 - 12/2005)
8. Lelakowski, Jacek: 5 articles (01/2015 - 01/2005)
9. Zipfel, Peter F: 5 articles (11/2014 - 09/2007)
10. Cook, H Terence: 5 articles (01/2014 - 09/2007)

Related Diseases

1. Sick Sinus Syndrome
2. Atrial Fibrillation
10/01/1999 - "We have performed a prospective, randomized, multicentre study to evaluate the efficacy of DDDR and DDD pacing modes in preventing paroxysmal atrial fibrillation (PAF) episodes in patients with brady-tachy syndrome and CI. "
03/01/2005 - "Several prospective randomised clinical trials have reported that atrial-based "physiologic" AAI(R)- or DDD(R)-pacing is associated with a lower incidence of paroxysmal and permanent atrial fibrillation than single-chamber ventricular pacing in patients with a conventional pacemaker indication. "
10/01/2002 - "The aim of the study was 1) to evaluate the cumulative survival and the events capable of modifying it, 2) to evaluate the stability of sinus rhythm, and 3) to try to identify patients who are at a higher risk of developing permanent atrial fibrillation after DDD implantation. "
10/01/2000 - "Accordingly, the aim of the present study was to correlate electrophysiological data, in terms of atrial refractoriness, conduction parameters, and propensity to atrial fibrillation induction, and the likelihood of atrial fibrillation after DDD device implantation. "
07/01/2015 - "At 3 years of follow-up, the atrial fibrillation burden was not significantly reduced with SafeR versus DDD (median 0.00%, interquartile range [0.00% to 0.23%] versus median 0.01%, interquartile range [0.00% to 0.44%], respectively, P=0.178]), despite a persistent reduction in the median proportion of ventricular-paced beats (10% with DDD compared to 0% with SafeR). "
3. Hypertrophic Cardiomyopathy (Asymmetric Septal Hypertrophy)
4. Atrioventricular Block
5. Heart Failure

Related Drugs and Biologics

1. Adenosine Triphosphate (ATP)
2. Hormones
3. Antigens
4. Phenobarbital (Luminal)
5. Methylcholanthrene
6. Ketoconazole (Nizoral)
7. Estradiol (Estrace)
8. Transferrin (beta 2 Transferrin)
9. Gonadal Steroid Hormones (Sex Hormones)
10. Immunoglobulin G (IgG)

Related Therapies and Procedures

1. Implantable Defibrillators (Implantable Cardioverter-Defibrillator)
2. Transplants (Transplant)
3. Arthroplasty
4. Drug Therapy (Chemotherapy)
5. Adrenalectomy